Cell therapy for advanced stomach or esophageal junction cancer
Part of Cancer, Digestive system clinical trials.
This trial tests an experimental cell therapy (IM96 CAR-T) for advanced stomach or gastroesophageal junction cancer that has not responded to standard treatments. The therapy uses your own immune cells, modified in a lab to target a protein (GUCY2C) found on cancer cells, potentially helping your body fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread to other parts of the body.
- Your cancer has not responded to or you could not tolerate standard treatments (including HER2-targeted therapy if your tumor is HER2-positive).
- You have at least one measurable tumor (seen on scans) and a tumor sample from the last 2 years that tests positive for a marker called GUCY2C.
- You are generally in good health (able to do light activities, with adequate heart, lung, kidney, and blood counts).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy called IM96 CAR-T, which targets a protein (GUCY2C) found on tumor cells. It is for people with advanced colorectal or stomach cancer that has not responded to standard treatments.
This trial tests a new cell therapy called satri-cel for people with stomach or gastroesophageal junction cancer that has a specific marker (CLDN18.2) and has been removed by surgery. The goal is to see if this treatment can prevent the cancer from coming back.
This trial tests an experimental therapy for people with advanced stomach or gastroesophageal junction cancer that has not responded to at least two prior treatments. The therapy targets a specific protein (CLDN18.2) found on cancer cells. The goal is to see if this approach can help control the disease.
This trial tests a new cell therapy (CT041) for people with advanced stomach or gastroesophageal junction cancer that has a specific marker called CLDN18.2. It is given after initial chemotherapy to try to keep the cancer from growing.
This trial tests a new type of cell therapy (CAR-NK cells) designed to attack gastric and esophageal junction cancers that have specific markers on their surface. The cells are engineered to recognize two targets on your cancer cells, which may help your immune system fight the cancer more effectively.
This trial tests a new type of immunotherapy called CAR-T cells, which are engineered to target a protein (Claudin18.2) found on some stomach and pancreatic cancer cells. The goal is to see if these specially designed cells can shrink tumors and slow the cancer's growth.
Hear when a new Adenocarcinoma of Esophagogastric Junction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.